Krystal Biotech Q1 2022 Earnings Report
Key Takeaways
Krystal Biotech reported a net loss of $50.0 million for the quarter ended March 31, 2022. The company's cash, cash equivalents, and investments totaled $468.0 million. A biologics license application for B-VEC remains on track to file in the US in 2Q 2022 and Marketing Authorization in the EU on track to file in 2H 2022.
B-VEC biologics license application remains on track for filing in the US in Q2 2022 and in the EU in 2H 2022.
FDA allows at-home dosing in the Open Label Extension Study of B-VEC for DEB treatment.
Jeune Aesthetics, Inc. reported positive clinical Phase 1 efficacy results for KB301.
The company closed the quarter with $468.0 million in cash, cash equivalents, and investments.
Krystal Biotech
Krystal Biotech
Forward Guidance
Krystal Biotech provided forward-looking statements regarding the clinical utility of B-VEC, at home dosing, the timing of the Company’s BLA submission and EMA marketing authorization application, timing of the KB407 Phase 1 clinical trial program in Australia and the U.S., timing of dosing the next cohort in the ongoing Phase 1/2 clinical trial of KB105, timing of an IND filing for KB104.